Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

UroGen Pharma (URGN) EBIT Margin: 2017-2025

Historic EBIT Margin for UroGen Pharma (URGN) over the last 7 years, with Sep 2025 value amounting to -99.65%.

  • UroGen Pharma's EBIT Margin fell 3004.00% to -99.65% in Q3 2025 from the same period last year, while for Sep 2025 it was -138.22%, marking a year-over-year decrease of 4452.00%. This contributed to the annual value of -107.06% for FY2024, which is 2783.00% down from last year.
  • According to the latest figures from Q3 2025, UroGen Pharma's EBIT Margin is -99.65%, which was up 41.78% from -171.17% recorded in Q2 2025.
  • In the past 5 years, UroGen Pharma's EBIT Margin ranged from a high of -62.09% in Q4 2023 and a low of -348.88% during Q1 2021.
  • Over the past 3 years, UroGen Pharma's median EBIT Margin value was -112.59% (recorded in 2024), while the average stood at -110.77%.
  • In the last 5 years, UroGen Pharma's EBIT Margin spiked by 63,499bps in 2021 and then slumped by 5,290bps in 2025.
  • Over the past 5 years, UroGen Pharma's EBIT Margin (Quarterly) stood at -123.13% in 2021, then soared by 1,102bps to -112.10% in 2022, then spiked by 5,002bps to -62.09% in 2023, then crashed by 5,050bps to -112.59% in 2024, then slumped by 3,004bps to -99.65% in 2025.
  • Its last three reported values are -99.65% in Q3 2025, -171.17% for Q2 2025, and -182.26% during Q1 2025.